Cognitive Enhancement Therapy for Alzheimer’s Disease

@article{Parnetti2012CognitiveET,
  title={Cognitive Enhancement Therapy for Alzheimer’s Disease},
  author={Lucilla Parnetti and Umberto Senin and Patrizia Mecocci},
  journal={Drugs},
  year={2012},
  volume={53},
  pages={752-768}
}
SummaryAlthough at present there is no definitive treatment or cure for Alzheimer’s disease, different pharmacological strategies are being actively investigated. At present, cholinergic therapy and nootropics and some neuronotrophic agents represent the available approaches to symptomatic treatment of Alzheimer’s disease. The use of cholinesterase inhibitors (ChEI) constitutes the best cholinergic approach to increase acetylcholine levels. Available data suggest that about 15 to 40% of… 

Role of aqueous extract of Azadirachta indica leaves in an experimental model of Alzheimer's disease in rats

Azadirachta indica might be effective in clinical AD by virtue of its cognition enhancement, antidepressant and antianxiety properties.

General and domain-specific neurocognitive impairments in deficit and non-deficit schizophrenia

The results indicate that cognitive flexibility is specifically impaired in deficit versus non-deficit patients and may therefore represent a core feature of this subtype of schizophrenia.

Design, synthesis and evaluation of indole derivatives as multifunctional agents against Alzheimer's disease.

Compound 6 was the most potent multifunctional agent showing better inhibitory activity than ladostigil in vitro on all enzymes tested and the potent neuroprotective ability of compound 6 make it a promising compound for further development.

Neuroprotective and Antiamnesic Effects of Mitragyna inermis Willd (Rubiaceae) on Scopolamine-Induced Memory Impairment in Mice

The results suggest that M. inermis leaf extract possess potential antiamnesic effects, and reversed the effects of scopolamine in mice.

Action-Based Cognitive Remediation for Individuals With Serious Mental Illnesses: Effects of Real-World Simulations and Goal Setting on Functional and Vocational Outcomes

Cognitive rehabilitative programs for serious mental illness that rely on computer-based training for neuroplasticity should ensure opportunities for active skill development and therapist-supported techniques to overcome challenges with generalizing cognitive effects to everyday outcomes.

Non-fatal endpoints alone and combined with fatal endpoints Nature of endpoint Non-fatal endpoints Stroke Retinal exudates Cardiac endpoints Heart failure Myocardial infarction Renal failure Fatal and non-fatal endpoints Stroke

The benefit of antihypertensive treatment weakened with advancing age, and for total mortality it decreased with lower systolic BP at entry, and the benefits of active treatment were not independently related to sex or to the presence of cardiovascular complications at entry.

Towards the rational design of novel drugs based on solubility, partitioning/distribution, biomimetic permeability and biological activity exemplified by 1,2,4-thiadiazole derivatives.

The influence of the compound structure on the physicochemical properties determining the bioavailability of drug-like substances was revealed and Solubility-permeability interplay has been assessed to evaluate potentialBioavailability of the compounds studied.

Antiamnesic Activity of Extracts and Fraction of Desmodium Gangeticum

Alkaloids are responsible for antiamnesic activity of D. gangeticum roots, which significantly reversed the amnesia induced by the scopolamine at the dose of 400 and 50 mg/kg, respectively, with respect to control.

Evaluation of Acetylcholinesterase Inhibitory and Antioxidative Activities of Rhus javanica

Results suggest that R. javanica may be possess potential benefits which might be useful in development of antioxidant and anti-alzheimer`s disease ingredient.

Studies on imidazopyridine derivatives as acetylcholinesterase inhibitors

Amac: Bu calismada, imidazo[1,2-a]piridinin bazi hidrazid turevlerinin sentezlenmesi ve antikolinesteraz aktivitelerinin arastirilmasi amaclandi. Yontem: Imidazo[1,2-a]piridin-2-karboksilik asid

References

SHOWING 1-10 OF 118 REFERENCES

Treatment of Alzheimer's disease: future directions

Protective approaches, which depend on the development of more effective methods for predicting and diagnosing AD, include the administration of nerve growth factor and other neurotrophins and the use of pharmacologic or genetic interventions to limit amyloid deposition and the formation of neurofibrillary tangles.

Alzheimer's disease and related disorders.

Mechanisms of cholinesterase inhibition in senile dementia of the alzheimer type: Clinical, pharmacological, and therapeutic aspects

It is suggested that an adequate test of the efficacy of ChE inhibition may await the use of new and improved ChE inhibitors that produce significantly fewer side effects and greater therapeutic effects than drugs presently being tested for efficacy in the treatment of SDAT patients.

A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

Treatment with tacrine resulted in a statistically significant reduction in the decline of cognitive function, although this reduction was not large enough to be detected by the study physicians' global assessments of the patients.

Alzheimer disease : therapeutic strategies

This volume provides reviews of advances in basic and clinical sciences that are relevant to understanding the aetiology, pathogenesis and diagnosis of Alzheimer's disease, with particular emphasis

Treatment of Alzheimer's disease with cholinergic drugs.

  • V. KumarM. Calache
  • Biology, Psychology
    International journal of clinical pharmacology, therapy, and toxicology
  • 1991
It is concluded that cholinergic drugs alone may not be the answer to treat Alzheimer disease patients and there seems to be a need to develop drug(s) which could affect several neurotransmitter or neuromodulator systems.

Inflammatory mechanisms in Alzheimer's disease: implications for therapy.

There is ample evidence supporting the hypothesis that inflammatory and immune mechanisms are involved in tissue destruction in Alzheimer's disease and clinical trials of anti-inflammatory/immunosuppressive drugs are necessary to determine whether alteration of these inflammatory mechanisms can slow the progression of Alzheimer's Disease.

Alzheimer's disease : basic mechanisms, diagnosis and therapeutic strategies

Partial table of contents: CLINICAL COURSE. Multidisciplinary Validation of Two Dementia Categories (N. Verma, et al.). NEUROPATHOLOGY: STRUCTURAL AND BIOCHEMICAL. Entorhinal Lesions in Dementia (H.

Long‐term effects of tacrine in alzheimer's disease: An open study

It is concluded that tacrine may temporarily delay the progression of symptoms of Alzheimer's disease and that administration of this drug can safely be prolonged with appropriate clinical supervision.
...